TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07564154: A Phase 1, Open-Label, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KT502 by Subcutaneous Administration in Adult Participants With Rheumatoid Arthritis

Sponsor: Kali Therapeutics, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$281,520

Rescue Site Savings

+$187,680

Unlock Full NCT07564154 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07564154 Rescue Dossier →